Eli Lilly & Co.
LLY NYS
Pharmaceuticals
Indianapolis, IN
Pharmaceuticals
Indianapolis, IN
2017 IW US 500 Rank | 51 |
2016 IW US 500 Rank | 57 |
Executive 1 | David A. Ricks, Chairman; President |
Executive 2 | Melissa S. Barnes, Senior Vice President; Chief Ethics Officer |
2016 Revenue (US$ Millions) | $21,222 |
Revenue Growth (%) | 6.33% |
2015 Revenue (US$ Millions) | $19,959 |
Net Income (US$ Millions) | $2,738 |
Common Shares Outstanding (Millions) | 1,100.88 |
Earnings Per Share (US$) | $2.58 |
Price to Earnings Ratio | 32.53 |
Total Equity (US$ Millions) | $14,008 |
Return on Equity (%) | 18.79% |
Long Term Debt (US$ Millions) | $8,368 |
Debt to Equity Ratio (%) | 0.60% |
Market Capitalization (US$ Millions) | $80,969 |
Total Assets (US$ Millions) | $38,806 |
Current Assets (US$ Millions) | $15,101 |
Inventories (US$ Millions) | $3,562 |
Current Liabilities (US$ Millions) | $10,987 |
Cost Of Goods Sold (US$ Millions) | $5,655 |
Asset Turnover | 0.57 |
Inventory Turnover | 1.61 |